Mersana Therapeutics' Q1 2024 Conference Call on May 9, 2024

CAMBRIDGE, Mass., May 02, 2024 – Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company, announced its plans to share business updates and financial results for the first quarter ending on March 31, 2024, on May 9, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time on that day. Interested parties can access the call by dialing 833-255-2826 for domestic calls or 412-317-0689 for international calls. Additionally, a live webcast of the presentation will be available on the “Investors & Media” section of the Mersana website, with a replay accessible for approximately 90 days post-conference.

Mersana Therapeutics focuses on creating and developing a pipeline of innovative antibody-drug conjugates (ADCs) aimed at treating cancers with substantial unmet medical needs. The company's efforts are geared toward providing new treatment options for patients through its proprietary ADC platforms, Dolasynthen and Immunosynthen. These platforms are at the core of Mersana’s pipeline of both wholly-owned and partnered product candidates that have the potential to address various types of cancer.

Among the candidates in Mersana’s pipeline are XMT-1660 and XMT-2056. XMT-1660 is a Dolasynthen ADC targeting B7-H4, which is a protein that can be overexpressed in certain cancers, making it a promising target for therapeutic intervention. On the other hand, XMT-2056 is an Immunosynthen ADC that targets a novel epitope of human epidermal growth factor receptor 2 (HER2), a protein involved in the growth of some cancer cells. Both candidates exemplify Mersana’s commitment to developing advanced treatments that leverage the unique capabilities of their ADC platforms to potentially improve cancer therapy outcomes.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!